Zebrafish Xenograft Model of Human Lung Cancer for Evaluating Osimertinib Resistance

About half of NSCLC patients with EGFR mutation had secondary mutation T790M after treatment with a first-generation tyrosine kinase inhibitor (TKI), Gefitinib. The third-generation of EGFR-TKI Osimertinib is suitable for patients with EGFR mutation and T790M mutation. However, drug screening for NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin-ying, Huang, Li-tang, Wu, Jia-qi, He, Ming-fang, Zhu, Su-hua, Zhan, Ping, Lv, Tang-feng, Song, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620834/
https://www.ncbi.nlm.nih.gov/pubmed/31346515
http://dx.doi.org/10.1155/2019/3129748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620834/
https://www.ncbi.nlm.nih.gov/pubmed/31346515
http://dx.doi.org/10.1155/2019/3129748

Ejemplares similares